Latest Breaking News On - Locally advanced unresectable - Page 1 : comparemela.com

Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results

Fourth-Quarter and Full-Year Sales Reflect Sustained Growth Across Oncology and Vaccines Fourth-Quarter Worldwide Sales Were $14.6 Billion, an Increase of 6% From Fourth Quarter 2022; Excluding.

United statesAdempas verquvoPatritumab deruxtecanRobertm davisDaiichi sankyo biologicsDaiichi sankyoHuman healthAfferent pharmaceuticalsExchange commissionMerck co incRestructuring programModerna incDrug administrationNet income attributable to merck co incPrometheus biosciences incHarpoon therapeutics inc

FDA Approves Pembrolizumab Plus Chemotherapy to Treat Metastatic HER2-Negative Gastric, Gastroesophageal Junction Adenocarcinoma

The approval makes pembrolizumab the first-line treatment for individuals with this cancer.

United statesLos angelesZeva wainbergUniversity of californiaLos angeles school of medicineUcla gi oncology programMerck research laboratoriesLos angeles schoolMarjorie greenFirst line treatmentLocally advanced unresectableNegative gastricGastroesophageal junction

China s National Medical Products Administration Accepts Astellas Biologics License Application for Zolbetuximab - Astellas Pharma (OTC:ALPMY)

TOKYO, July 31, 2023 /PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products

United statesUnited kingdomMoitreyee chatterjee kishoreNaoki okamuraWorld health organizationAmerican society of clinical oncologyEnd results programNational cancer instituteOncology developmentPrnewswire astellas pharma incChina national medical products administrationAstellas pharma incAmerican cancer societyDrug evaluationBiologics license applicationSenior vice president

China s National Medical Products Administration Accepts Astellas Biologics License Application for Zolbetuximab

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the Center for Drug Evaluation (CDE) of the.

United statesUnited kingdomMoitreyee chatterjee kishoreNaoki okamuraOncology developmentPrnewswire astellas pharma incAmerican society of clinical oncologyChina national medical products administrationAstellas pharma incAmerican cancer societyWorld health organizationEnd results programNational cancer instituteDrug evaluationBiologics license applicationSenior vice president

European Medicines Agency Accepts Astellas Marketing Authorization Application for Zolbetuximab

European Medicines Agency Accepts Astellas Marketing Authorization Application for Zolbetuximab
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomMoitreyee chatterjee kishoreNaoki okamuraAmerican cancer societyOncology developmentEuropean medicines agencyAstellas pharma incEuropean commissionCommittee for medicinal products human useAmerican society of clinical oncologyNational cancer institutePrnewswire astellas pharma incWorld health organizationEnd results programSenior vice president